非酒精性脂肪性肝病：回顾历史,展望未来

doi:10.3969/j.issn.1672-5069.2016.02.001

Abstract

Zeng Mingde. Achievements and perspectives in nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 129-131.

[1] Sanyal AJ. NASH:A global health problem. Hepatol Res,2011, 41（7）:670-674.
[2] Tiniakos DG,Vos MB,Brunt EM. Nonalcoholic fatty liver disease:pathology and pathogenesis. Annu Rev Pathol,2010,5：145-171.
[3] Than NN,Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis,2015,239（1）:192-202.
[4] Tilg H,Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis. Hepatology,2010,52（5）:1836-1846.
[5] Cusi K. Role of obesity and lipotoxicity in the development of
nonalcoholic steatohepatitis:pathophysiology and clinicalimplications. Gastroenterology,2012,142（4）:711-725,e6.
[6] Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis:the central role of nontriglyceride fatty acid metabolites. Hepatology,2010,52（2）:774-788.
[7] Esser N,Legrand-Poels S,Piette J,et al. Inflammation as a link between obesity,metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract,2014,105（2）:141-150.
[8] LaBrecque DR,Abbas Z,Anania F,et al. World Gastroenterology Organisation global guidelines:Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol,2014,48（6）:467-473.
[9] EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol, 2015,63（1）:237-264.
[10] Musso G,Gambino R,Cassader M,et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology,2010,52（1）:79-104.
[11] 曾民德. PIVENS及其相关的后续研究与非酒精性脂肪性肝病治疗的未来方向. 肝脏,2014,19（1）:53-56.
[12] Sanyal AJ,Friedman SL,McCullough AJ,et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology,2015,61（4）:1392-1405.
[13] Anstee QM,McPherson S,Day CP. How big a problem is non-alcoholic fatty liver disease BMJ,2011,343（d38）:97.
[14] Nascimbeni F,Pais R,Bellentani S,et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol,2013, 59（4）:859-871.
[15] Ratziu V,Goodman Z,Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol,2015,62（Suppl 1）:S65-75.
[16] Matherly SC,Puri P. Mechanisms of simple hepatic steatosis: not so simple after all. Clin Liver Dis,2012,16（3）:505-524.
[17] Byrne CD,Targher G. NAFLD:a multisystem disease. J Hepatol,2015,62（Suppl 1）:S47-64.
[18] Marchesini G,Mazzotti A. NAFLD incidence and remission:only a matter of weight gain and weight loss J Hepatol,2015,62（1）: 15-17.
[19] Caldwell SH,Ikura Y,Iezzoni JC,et al. Has natural selection in human populations produced two types of metabolic syndrome （with and without fatty liver） J Gastroenterol Hepatol,2007,22 （Suppl）:S11-19.
[20] Armstrong MJ,Adams LA,Canbay A,et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology, 2014,59（3）:1174-1197.
[21] Hotamisligil GS. Inflammation and metabolic disorders. Nature, 2006,444（7121）:860-867.
[22] Gallagher EJ,LeRoith D. Epidemiology and molecular mechanisms tying obesity,diabetes,and the metabolic syndrome with cancer. Diabetes Care,2013,36 （Suppl 2）:S233-239.
[23] Arnold M,Pandeya N,Byrnes G,et al. Global burden of cancer attributable to high body-mass index in 2012:a population-based study. Lancet Oncol,2015,16（1）:36-46.
[24] Stickel F,Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma:mechanisms and implications. Gut,2010,59（10）:1303-1307.
[25] Tsedensodnom O,Sadler KC. ROS:redux and paradox in fatty liver disease. Hepatology,2013,58（4）:1210-1212

Achievements and perspectives in nonalcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[2]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[3]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[4]	Zeng Minde. Mechanisms of lipotoxicity in pathogenesis of nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 153-156.
[5]	Wang Qian,Guo Ping. Application of fibroscan and anthropometric parameters in diagnosis of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 754-755.
[6]	Li Yan，Wang Caihua.. Hot spots in dietary therapy in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 529-531.
[7]	Pang Xiaoning，Liu Yanjun.. A comparative study of liraglutide,sitagliptin and pioglitazone in the treatment of patients with nonalcoholic fatty liver diseases and type 2 diabetes mellitus [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 604-605.
[8]	Guan Jun, Xu Ye. Risk factors of nonalcoholic fatty liver diseases in adolescents [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 347-349.
[9]	Sun Changgui， Zeng Jing，Sun Wanlu，et al.. Changes of estimated glomerular filtration rates in healthy check-up adults with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 165-170.
[10]	Cui Xiaomeng, Liu Xin, Shi Haitao, et al.. Effects of diammonium glycyrrhizinate lipid ligand on AMPKα signaling pathways in rats with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 55-59.
[11]	Liang Qianfei, Zhao Caiyan. Hepatocellular carcinoma in patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 113-116.
[12]	Yu Shenglei，Weng Xinhua. Antimicrobial therapy in adult patients with bacterial liver abscess [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 337-339.
[13]	Tan Pufang，Nan Yuemin，Wang Rongqi，et al.. Impact of Fuzheng Huayu recipe on the expression of angiogenic growth factor in mice with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 352-355.
[14]	Zhou Long， Zhang Qian，She Huiyuan. Ultrasonography and magnetic resonance imaging in diagnosis of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 437-440.
[15]	Hu Chenbo, Li Zhongping, Pan Jieping, et al. Application of intima-media thickness of carotid artery in diagnosis of phlegm-stasis syndrome in patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 38-42.